Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

How Can the Generics Industry Up its Game on Essential Medicine Access?

In an op-ed for Pharma Boardroom, Claudia Martínez, Research Programme Manager for the Foundation's Generic & Biosimilar Medicines Programme, writes about opportunities generic and biosimilar medicine manufacturers can tap into to ensure access to essential products they produce. Martínez draws on the findings from the Foundation's latest report that profiles leaders in the generic and biosimilar medicines industry.

Date

29 September 2023

Direct links

Read the full op-ed

Frequently, R&D-based pharmaceutical companies are the ones at the centre of conversations about access to medicine in LMICs – especially given the need to rapidly expand access to their innovative, high-profile, and sometimes-pricey treatments. But the truth is that the majority of pharmaceutical products that people living in the world’s poorest nations rely upon are actually generic medicines. In some LMICs, generics make up as much as 80 percent of the market share, making them a vital lifeline for patients in these countries. What’s more, the vast majority of medicines that the World Health Organization deems ‘essential medicines’ have already gone off patent.

This gives generic and biosimilar medicine manufacturers tremendous power when it comes to expanding access. These companies’ decisions about manufacturing, registration, pricing, and supply in LMICs can have a significant impact on whether an essential medicine ultimately becomes available, and whether it is made affordable for the people who need it.

Generic medicine manufacturers have often been celebrated as the champions of affordable access. As patented medications lose their exclusivity, these companies step up to produce and distribute more affordable versions of brand-name drugs, opening doors to wider access. Look no further than the remarkable progress in access to HIV treatment, where the introduction of generic versions has helped drive down the cost of antiretroviral drugs by more than 99 percent over the last decade. This has made these medicines more accessible to a larger number of people, especially in LMICs.

Read the full op-ed on the Pharma Boardroom website.

Claudia Martínez

Director of Research

cmartinez@accesstomedicinefoundation.org

Get in touch

Sectors & Research

Learn more about our Generic & Biosimilar Medicines Programme
Featured News

Spotlight on the generics industry: New analysis looks at access efforts of 5 major companies

26 September 2023
Event

Joint event with World Economic Forum on the evolving role of generics – Meeting Report

21 June 2023

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved